Table 2.
Name | Authors | Number of Participants | Country of Origin | Comparison Arm | Follow-Up Period | Summary of Results |
---|---|---|---|---|---|---|
Serenoa repens (Saw Palmetto) | Bent et al., 2006 [68] | 225 | United States | Placebo | 14 months | No significant reduction in prostate volume (mean difference −1.22 cc), peak flow (mean difference 0.43 mL/s), or residual volume (mean difference −4.51 mL), after treatment with Serenoa repens compared with placebo. |
Serenoa repens (Saw Palmetto) | Barry et al., 2011 [30] | 369 | United States | Placebo | 72 weeks | No significant difference in American Urological Association Symptom Index (AUASI) scores after treatment with Serenoa repens compared with placebo (mean difference −0.79 points). |
Serenoa repens (Saw Palmetto) | Hizli & Uygur 2007 [69] | 60 | Turkey | Tamsulosin | 6 months | No significant improvement in peak flow (mean difference −0.4 mL/s), International Prostate Symptom Scores (IPSS) (mean difference 1.5 points), prostate volume (mean difference −0.3 cc), or residual volume (mean difference 4.6 mL), after treatment with Serenoa repens compared with tamsulosin (mean difference −0.4 mL/s). |
Pygeum africanum (Prunus Africana) | Barlet et al., 1990 [70] | 263 | Germany, France, and Austria | Placebo | 60 days | Improvement in peak flow rate after treatment with pygeum africanum compared with placebo (mean difference 1.1 mL/s). No significant improvement in residual volume rate after treatment with pygeum africanum compared with placebo (mean difference -12.6 mL). |
Pygeum africanum (Prunus Africana) | Chatelain et al., 1999 [36] | 209 | France | None | 12 months | Single or bi-daily dosing had similar efficacy. IPSS scores improved from baseline by between 35 and 38%. Qmax increased by between 1.63 and 2.02 mL/s. |
Cucurbita pepo | Theil et al., 2022 [39] | 130 | Germany | None | 24 months | IPSS was improved at 12 months, on average, by 4.7 points. IIEF-5 scores indicated a minimal impact on sexual function. |
Cucurbita pepo | Zerafatjou et al., 2021 [38] | 73 | Iran | Tamsulosin | 3 months | No significant difference in International Prostate Symptom Scores (IPSS) after treatment with cucurbita pepo compared with tamsulosin (mean difference 1.81 points). No significant difference in prostate volume after treatment with cucurbita pepo compared with tamsulosin (mean difference 0.72 cc). No significant difference in peak flow after treatment with cucurbita pepo compared with tamsulosin (mean difference 1.71 mL/s). |
Urtica dioica | Safarinejad 2005 [42] | 558 | Iran | Placebo | 6 months | Significant improvement in peak flow (mean difference 4.8 mL/s), IPSS (mean difference 6.5 points), and residual volume (mean difference 37 mLs), after treatment with urtica dioica, compared with placebo. |
Urtica dioica | Hosseinabadi et al., 2014 [71] | 248 | Iran | Prazosin | 2 months | 3 g/5 g/7 g, in combination, significantly improved IPSS scores after treatment, compared to treatment with prazosin alone (mean change in IPSS 10.46 points in the 7 g urtica dioica group compared with 2 points in the control group) |
Epilobium angustifolium | Esposito et al., 2021 [44] | 128 | Italy | Placebo | 6 months | Epilobium angustifolium was significantly more effective than placebo for IPSS scores (mean difference 2.5 points) and residual volume (mean difference 4.3 mL), but not for prostate volume (mean difference −1.3 cc). |
Hypoxis hemerocallidea | Berges et al., 1995 [72] | 200 | Germany | Placebo | 6 months | Peak flow (mean difference 4.1 mL/s), IPSS placebo (mean difference 5.3 points), and residual volume (mean difference 23.8 mL) were improved more in β-sitosterol (the active ingredient in hypoxis hemerocallidea) than placebo (mean difference 4.1 mL/s). There was no difference between prostate volume after treatment with β-sitosterol compared with placebo. |
Hypoxis hemerocallidea | Klippel et al., 1997 [20] | 177 | Germany | Placebo | 6 months | Hypoxis hermerocallidea was significantly more effective than placebo for IPSS scores (mean difference 5.4 points), residual volume (mean difference 33.5 mL), and peak flow (mean difference 4.5 mL/s). |
Pinus pinaster | Pavone et al., 2010 [47] | 80 | Italy | None | 12 months | Combination therapy (serenoa repens 320 mg, urtica dioica 120 mg, and pinus pinaster 5 mg)—85% of patients reported symptomatic improvement in LUTS. No improvement in prostate size or peak volume. |
Solanum lycopersicum (Lycopersicum esculentum) | Lambertini et al., 2021 [49] | 250 | Italy | Alfuzosin | 12 months | Combination therapy (alfuzosin, serenoa repens, solanum lycopersicum, lycopene, and bromelain) compared with alfuzosin alone. Combination therapy significantly decreased IPSS compared to the control group (mean difference of 5 points) and residual volume compared with the control (mean difference of 23 mL). |
Roystonea regia | Guzmán et al., 2019 [51] | 100 | Cuba | Terazosin | 6 months | D-004 (containing roystonea regia) was more effective than terazosin in reducing the IPSS score (mean difference of 1.1 points). There was no significant difference between the two groups with regard to effects on prostate volume and residual volume. |
Secale cereale | Xu et al., 2008 [55] | 240 | China | Lower dose of secale cereale (375mg) | 4 years | Cernilton (containing secale cereale), administered at 750 mg daily, was more efficacious than 375 mg daily at reducing IPSS (mean difference 5.3 points), residual volume (mean difference 11.1 mL), and peak flow (mean difference 9.5 mL/s) |
Linum usitatissimum | Zhang et al., 2008 [57] | 78 | China | Placebo | 4 months | Linum usitatissimum did not show significantly improved IPSS or peak flow over placebo. Despite this, treatment for 4 months with 600 mg of linum usitatissimum reduced IPSS by 6.88 points and improved peak flow by 2.7 mL/s. |